GAD-alum immunotherapy in type 1 diabetes expands bifunctional Th1/Th2 autoreactive CD4 T cells

AIMS/HYPOTHESIS: Antigen-specific therapy aims to modify inflammatory T cell responses in type 1 diabetes and restore immune tolerance. One strategy employs GAD65 conjugated to aluminium hydroxide (GAD-alum) to take advantage of the T helper (Th)2-biasing adjuvant properties of alum and thereby regu...

Descripción completa

Detalles Bibliográficos
Autores principales: Arif, Sefina, Gomez-Tourino, Iria, Kamra, Yogesh, Pujol-Autonell, Irma, Hanton, Emily, Tree, Timothy, Melandri, Daisy, Hull, Caroline, Wherrett, Diane K., Beam, Craig, Roep, Bart O., Lorenc, Anna, Peakman, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228993/
https://www.ncbi.nlm.nih.gov/pubmed/32248243
http://dx.doi.org/10.1007/s00125-020-05130-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7228993/
https://www.ncbi.nlm.nih.gov/pubmed/32248243
http://dx.doi.org/10.1007/s00125-020-05130-7

Ejemplares similares